The wide range of application and the great potential in overcoming drug resistance and targeting non-proprietary targets, research and development in Protein Degrader field has been hot in recent years. Protein Degrader,Read More…
On December 14, 2020, Arvinas released the latest clinical data of ARV-471 and ARV-110, which showed strong therapeutic potential. As soon as the news was released, Arvinas’s share price doubled, with aRead More…
Protein Degrader, of which the full name is proteolysis-targeting chimera, looks like a dumbbell and mainly consists of a linker, a ligand of interest protein, and a ligand recruiting E3 ubiquitin ligase.Read More…
In addition to the T-cell Lymphoma,T-cell Acute Lymphoblastic Leukaemia mentioned in our previous article, there are also related studies of protac in other blood diseases. Next, let’s analyze the research of protacRead More…
Proteolysis targeted chimera (Protein Degrader) is a rapidly developed technology in recent years, which provides the possibility for many undruggable targets, and has become the focus of protein drug researchers. Hematologic malignanciesRead More…
In recent years, targeted protein degradation chimera (Protein Degrader) as a novel way to induce protein degradation has become a new drug discovery strategy. Compared with traditional protein inhibitor drugs, it hasRead More…
Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT family, which responds to a variety of cytokines, growth factors and other signals and activates the expression ofRead More…
Among the drugs developed in Arvinas, ARV-110 is the first oral PRAOTC small molecule drug to enter clinical trials in the field of proteolytic targeted chimerism, selectively targeting the degradation of androgenRead More…